Hepalatide ameliorated progression of nonalcoholic steatohepatitis in mice

Hepalatide ameliorated progression of nonalcoholic steatohepatitis in mice

Background: No FDA-approved medications are available for the treatment of nonalcoholic steatohepatitis (NASH). The present study aimed to assess the effects of Hepalatide, a sodium taurocholate cotransporting polypeptide (NTCP) receptor-binding agent, on metabolic and histopathologic changes of a m...

Full description

Bibliographic Details
Main Authors: Xue-Jing Liu, Chang Liu, Liu-Yan Zhu, Cui-Li Fan, Chen Niu, Xiu-Ping Liu, Hong-Li Liu, Jian Wu
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Nonalcoholic steatohepatitis
Hepalatide
Bile acids
Hepatic fibrosis
Insulin resistance
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332220302444

Internet

http://www.sciencedirect.com/science/article/pii/S0753332220302444

Similar Items